Figure 2.

(A) Kaplan–Meier analysis of the cumulative risk of major and clinically relevant non-major bleeding (black bars), and any bleeding events (white bars) at 6 months (safety analysis set). (B) Kaplan–Meier analysis of the cumulative risk of the primary safety endpoint of major and clinically relevant non-major bleeding events for the three total daily doses of darexaban (10, 30, and 60 mg). Cumulative incidences are calculated using Kaplan–Meier estimates and presented as relative to 1 (e.g. 0.06 represents 6%). CRNM, clinically relevant non-major; b.i.d., twice daily; o.d., once daily.